Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Across the recent three months, 6 analysts have shared their insights on Conmed (NYSE:CNMD), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 4 | 1 | 1 | 0 | 0 |
Last 30D | 2 | 1 | 1 | 0 | 0 |
1M Ago | 1 | 0 | 0 | 0 | 0 |
2M Ago | 0 | 0 | 0 | 0 | 0 |
3M Ago | 1 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Conmed, presenting an average target of $89.5, a high estimate of $107.00, and a low estimate of $71.00. Observing a downward trend, the current average is 7.42% lower than the prior average price target of $96.67.
The standing of Conmed among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Matt O'Brien | Piper Sandler | Lowers | Overweight | $80.00 | $95.00 |
Rick Wise | Stifel | Lowers | Buy | $76.00 | $88.00 |
Vik Chopra | Wells Fargo | Lowers | Equal-Weight | $71.00 | $77.00 |
Mike Matson | Needham | Lowers | Buy | $97.00 | $106.00 |
Mike Matson | Needham | Lowers | Buy | $106.00 | $107.00 |
Mike Matson | Needham | Maintains | Buy | $107.00 | $107.00 |
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Conmed's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Conmed analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Conmed's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 5.69%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Conmed's net margin excels beyond industry benchmarks, reaching 6.31%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Conmed's ROE excels beyond industry benchmarks, reaching 2.33%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.86%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 1.16, Conmed adopts a prudent financial strategy, indicating a balanced approach to debt management.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CNMD